By Fineline Cube 
China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24 to outline its 2025 medical device inspection agenda. The meeting highlighted achievements from 2024, including enhanced product quality and public safety, while emphasizing stricter compliance frameworks to address evolving industry risks.
2024 Progress and 2025 Priorities
In 2024, provincial regulators and testing agencies implemented the “four strictest” mandates—strictest standards, supervision, penalties, and accountability—to complete national sampling inspections. This bolstered accountability under the NMPA’s “pro-development, pro-safety” governance model. For 2025, authorities will optimize inspection mechanisms, streamline interagency coordination, and prioritize high-risk devices to preempt safety gaps.
Systemic Upgrades to Safeguard Public Health
The NMPA’s Device Supervision Department, China Inspection Institute, and provincial regulators pledged to deepen risk analysis and data-driven oversight. Focus areas include strengthening post-market surveillance, accelerating non-compliant product recalls, and leveraging AI for inspection efficiency. These steps aim to align China’s medical device ecosystem with global regulatory benchmarks.-Fineline Info & Tech